Immunicon Achieves Endpoint in Its Pivotal Clinical Trial in Metastatic Androgen-Independent Prostate Cancer (RedNova)
Immunicon Corporation (NASDAQ-GM:IMMC) announced today that the Company met its primary endpoint associated with its pivotal clinical trial in metastatic androgen-independent prostate cancer.

Global acceptance of agricultural biotechnology continues to grow with record numbers of farmers planting biotech crops ... (SeedQuest)
Global acceptance of biotech crops increased in 2006, with global biotech crop acreage reaching 252 million acres in 22 countries according to the International Service for the Acquisition of Agri-biotech Applications (ISAAA)*. Global biotech crop acreage increased more than 13 percent from 2005, when 222 million acres of biotech crops were grown in 21 countries.

Using Design Controls to Reduce Time to Market (Medical Device Link)
FDA s quality system regulation (QSR) is often perceived by medical product developers as unnecessary overhead. Software developers, in particular, often see it as a nuisance that delays the completion of the development of the product. Actually, just the opposite may be true.